Immunic

formerly Immunic TherapeuticsIPO

Home - Immunic Therapeutics

Public · New York, United States · Founded 2016 · $694.9M raised

Headquarters
New York, New York
Founded
2016
Business Model
B2B
Website
imux.com
Total Funding
$694.9M
Last Round
$400.0M Private EquityFeb 2026
Rounds
4
Type
Public

About

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and autoimmune diseases. Its lead program, vidofludimus calcium (IMU-838), is in Phase 3 trials for relapsing multiple sclerosis. Founded in 2016 as Immunic AG in Germany, the company redomiciled to the United States in 2019 and is headquartered in New York City.

Summary

Immunic is a Biotech company based in New York, United States, founded in 2016. It has raised $694.9M in total across 4 rounds, most recently a $400.0M Private Equity round in Feb 2026. Investors include High-Tech Grunderfonds, Boehringer Ingelheim Venture Fund and Omega Funds.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Private EquityPrivate EquityFeb 2026
$400.0M

Sign up to see all 4 events

Funding: Series A through Private Equity. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Immunic on Indexed.vc
<a href="https://indexed.vc/companies/immunic"><img src="https://indexed.vc/api/badge/company/immunic" alt="Immunic on Indexed.vc" width="260" height="76" /></a>